Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study,Arthritis & Rheumatology

当前位置： X-MOL 学术 › Arthritis Rheumatol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study
Arthritis & Rheumatology ( IF 13.3 ) Pub Date : 2022-07-13 , DOI: 10.1002/art.42280
Laura C Coates ₁ , Iain B McInnes ₂ , Joseph F Merola ₃ , Richard B Warren ₄ , Arthur Kavanaugh ₅ , Alice B Gottlieb ₆ , Laure Gossec ₇ , Deepak Assudani ₈ , Rajan Bajracharya ₈ , Jason Coarse ₉ , Barbara Ink ₈ , Christopher T Ritchlin ₁₀

Affiliation

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, University of Oxford and Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford, UK.
University of Glasgow, Glasgow, UK.
Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts.
Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, Manchester, UK.
Division of Rheumatology, Allergy, and Immunology, UC San Diego School of Medicine, La Jolla, California.
Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York.
Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Rheumatology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
UCB Pharma, Slough, UK.
UCB Pharma, Raleigh, North Carolina.
Department of Medicine, University of Rochester, New York, New York.